Scientists at the University of Michigan Rogel Cancer Center have found a promising new way to fight one of the most ...

More information: Zhigang Nian et al, Interleukin-34-orchestrated tumor-associated macrophage reprogramming is required for ...

The groups interested in studying p53 next wanted to investigate its interactions with T antigen. Scientists made these findings as the theory of oncogenes, the idea that mutated host growth-promoting ...

The ATM gene (mutated in the disease ataxia telangiectasia) activates the p53 tumor suppressor protein in response to DNA damage, explaining the higher incidence of cancer in AT patients.

We also demonstrated that, in vivo when the ligand-liposome encapsulated wt p53 was injected I.V., preexisting SCCHN and prostate cancer xenografts completely regressed after radiotherapy.

PMV Pharmaceuticals, Inc.’s PMVP share price has surged by 7.83%, which has investors questioning if this is right time to ...

Shelley L. Berger, PhD, FAACR, has been recognized for her outstanding contributions to cancer research by the American Association for Cancer Research (AACR) with the 2025 AACR-Women in Cancer ...

It is involved in the development and commercialization of novel cancer therapeutics that reactivate mutant p53 tumor suppressor protein. The company was founded by Vladimir Bykov, Klas Gota Wiman ...